l General Information |
Product Name | Rasagiline Mesylate |
General description | Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. |
Synonym | TVP-1012; methanesulfonic acid; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine |
Purity | ≥98.0%(HPLC) | CAS Number | 161735-79-1 |
Formula | C13H17NO3S | Molecular Weight | 267.343 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White to Tan Powder |
Solubility(25°C) | DMSO | ≥45mg/mL |
Ethanol | ≥45mg/mL |
Water | ≥45mg/mL |
l Biological Information |
Biochem/Physiol
Actions | Rasagiline is an inhibitor of monamine oxidase used as adjunctive therapy in combination with levodopa and carbidopa in the management of Parkinsons disease. Rasagiline has been associated with a low rate of serum enzyme elevations during treatment, but has not been ed to instances of clinically apparent acute liver injury. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
